Topiramate-induced weight loss is possibly due to the blockade of conditioned and automatic processes by Khazaal, Yasser & Zullino, Daniele
LETTER TO THE EDITORS
Topiramate-induced weight loss is possibly due
to the blockade of conditioned and automatic processes
Yasser Khazaal & Daniele Fabio Zullino
Received: 22 March 2007 /Accepted: 23 April 2007 /Published online: 14 July 2007
# Springer-Verlag 2007
Sir,
We read with great interest the paper of Tremblay and
others [1] on topiramate’s effect on weight, energy balance,
appetite and satiety. They studied topiramate-induced
weight loss (WL) in obese males who were, however,
instructed not to start any diet or exercise program intended
to induce WL during the course of the study. Most
interestingly, the authors investigated among other things
the desire to eat, hunger, fullness and prospective food
consumption. The WL that clearly appeared during the
study could not be explained by a modification of energy
expenditure. In absence of any dietary intervention, a
general reduction in food intake was observed in patients
receiving topiramate. An anorectic effect of topiramate, as
reported for other anti-obesity agents [2] was, then,
expected. Actually, no variations were found on hunger,
fullness or desire to eat under topiramate treatment.
Thus, as neither appetite nor energy expenditure was
affected, other mechanisms underlying the food intake
process have to be hypothesized as being affected by
topiramate. Eating behavior is not only linked to appetite
mechanisms but may largely be maintained by a compul-
sive and/or an addictive component, both of which are
generally associated with environmental cues and automatic
processes [3]. These processes have been found to depend
on the glutamatergic system, where the activation of the α-
amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid
(AMPA) receptor is critical for their expression. The AMPA
receptors (AMPAR) antagonists are known to block
reinstatement of conditioned and automatic processes [4].
Topiramate has multiple mechanisms of action, including
blocking the AMPA/kainate subtype of the glutamate receptor
[5]. Given the role of AMPAR in the expression of
conditioned responses and topiramate’s AMPAR-antagonistic
properties, one can hypothesize that topiramate-induced WL,
which was not due to modification of energy expenditure nor
to an anorectic effect, was possibly mediated by topiramate’s
effect on conditioned and automatic processes.
This observation is in line with observations on top-
iramate’s effects on various addictive and/or compulsive
behaviors such as alcohol addiction [6], nicotine addiction
[7], sexual compulsive behavior [8], pathological gambling
[9] as well as binge-eating disorder [10]. It could be of high
interest to investigate the importance of automatic and
conditioned processes in overeating in obese patients who
probably could have better response to topiramate treatment.
A further study including an investigation of conditioned
and automatic processes in eating, for example by a
cognitive and behavioral analysis of eating patterns before
and during topiramate treatment, could highlight this
subject.
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